Congress tightens 340B drug discount rules—but may shrink access for the poorest patients.

What it does

The SUSTAIN 340B Act tightens oversight and accountability in the 340B drug discount program, which allows certain healthcare entities (hospitals, clinics, safety-net providers) to purchase drugs at steep discounts for uninsured and low-income patients. The bill requires covered entities to register contract pharmacies, maintain detailed records, report how they use savings, and submit to audits by HHS and drug manufacturers. It also restricts which patients qualify for the discount, limits how entities can use referral prescriptions, and imposes penalties for violations—including temporary program exclusion and civil fines.

Why we flagged it

The bill's core mechanism is regulatory tightening: it adds registration, audit, reporting, and eligibility-verification requirements to the 340B program. While framed as 'integrity' and 'transparency,' the operative effect is to constrain how covered entities operate and who qualifies for discounts, shifting power toward HHS and manufacturers.

What the text implies

• Narrowing the 'patient' definition (requiring documented outpatient service within 2 years, auditable medical records) may exclude homeless, episodic-care, or highly mobile populations who are among the program's intended beneficiaries.
• The 20% cap on referral prescriptions and mandatory audits for entities exceeding it may discourage covered entities from referring patients to specialists outside their system, potentially fragmenting care coordination.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical manufacturers (audit rights, data access, ability to challenge eligibility); HHS/government (expanded enforcement and audit authority)